Literature DB >> 6281432

Differences in the ability of human peripheral blood monocytes and in vitro monocyte-derived macrophages to produce superoxide anion: studies with cells from normals and patients with chronic granulomatous disease.

R A Musson, L C McPhail, H Shafran, R B Johnston.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281432

Source DB:  PubMed          Journal:  J Reticuloendothel Soc        ISSN: 0033-6890


× No keyword cloud information.
  7 in total

1.  Arachidonic acid turnover in response to lipopolysaccharide and opsonized zymosan in human monocyte-derived macrophages.

Authors:  C C Leslie; D M Detty
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

2.  Decreased superoxide production, degranulation, tumor necrosis factor alpha secretion, and CD11b/CD18 receptor expression by adherent monocytes from preterm infants.

Authors:  D Kaufman; L Kilpatrick; R G Hudson; D E Campbell; A Kaufman; S D Douglas; M C Harris
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

3.  Changes in respiratory burst activity during human monocyte differentiation in suspension culture.

Authors:  J M Zeller; J Caliendo; T F Lint; D J Nelson
Journal:  Inflammation       Date:  1988-12       Impact factor: 4.092

4.  Human monocyte maturation/differentiation during in vitro culture.

Authors:  R A Musson
Journal:  Surv Immunol Res       Date:  1983

5.  The development of cytochrome b-245 in maturing human macrophages.

Authors:  R C Garcia; A R Cross; A W Segal
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

6.  Human serum induces maturation of human monocytes in vitro. Changes in cytolytic activity, intracellular lysosomal enzymes, and nonspecific esterase activity.

Authors:  R A Musson
Journal:  Am J Pathol       Date:  1983-06       Impact factor: 4.307

7.  Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells.

Authors:  A Szuro-Sudol; C F Nathan
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.